Evaluation of the anxiolytic effects of chrysin, a Passiflora incarnata extract, in the laboratory rat

AANA Journal

Volumn 75, Issue 5, 2007, Pages 333-337

  Brown, Eric ^a   Hurd, Neil S ^a   McCall, Suzanne ^b   Ceremuga, Thomas E ^c  

^a Brooke Army Medical Center ^*

^b BROOKE ARMY MEDICAL CENTER   (United States)

^c BAYLOR UNIVERSITY   (United States)

Author keywords

Anxiety; Chrysin; Elevated plus maze; Passiflora incarnata

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE RECEPTOR; CATECHOLAMINE; CHRYSIN; CORTICOSTERONE; DIMETHYL SULFOXIDE; FLUMAZENIL; MIDAZOLAM; PASSIFLORA INCARNATA EXTRACT; PLACEBO;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HORMONE DETERMINATION; MALE; MAZE TEST; MEDICINAL PLANT; NONHUMAN; RAT; SPRAGUE DAWLEY RAT; STATISTICAL ANALYSIS; TRANQUILIZING ACTIVITY;

EID: 35348870359     PISSN: 00946354     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Anxiety Disorders of America. Statistics and Facts About Anxiety Disorders. Available at: http://www.adaa.org/aboutADAA/Pressroom/ STATS&Facts.asp. Accessed February 12, 2005.
2. US Public Health Service. Mental Health: A Report of the Surgeon General. Etiology of Anxiety Disorders. Available at: http://www.surgeongeneral.gov/ library/mentalhealth/chapter4/sec2.html. Accessed February 12, 2005.
3. Selye H. Further thoughts on "stress without distress." Med Times. 1976;104:124-144.
4. Kain ZN, Sevarino F, Pincus S, et al. Attenuation of the preoperative stress response with midazolam: effects on postoperative outcomes. Anesthesiology. 2000;93:141-147.
5. Weissman C. The metabolic response to stress: an overview and update. Anesthesiology. 1990;73:308-327.
6. Huffman JC, Stern TA. The use of benzodiazepines in the treatment of chest pain: a review of the literature. J Emerg Med. 2003;25:427-437.
7. Kraft M. Holistic issues in the preoperative period. Int Anesthesiol Clin. 2002;40:201-212.
8. Agelink MW, Majewski TB, Andrich J, Mueck-Weymann M. Short-term effects of intravenous benzodiazepines on autonomic neurocardiac regulation in humans: a comparison between midazolam, diazepam, and lorazepam. Crit Care Med. 2002;30:997-1006.
9. Johnson TN, Rostami-Hodjegan A, Goddard JM, Tanner MS, Tucker GT. Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis. Br J Anaesth. 2002;89:428-437.
10. Hardman J, Limbird L. Goodman & Gilman's The Pharmacologic Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill; 2001.
11. Stoelting R. Benzodiazepines. In: Pharmacology & Physiology in Anesthetic Practice. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:126-139.
12. Dhawan K, Dhawan S, Chhabra S. Attenuation of benzodiazepine dependence in mice by a tri-substituted benzoflavone moiety of Passiflora incarnata Linneaus: a non-habit forming anxiolytic. J Pharm Pharm Sci. 2003;6:215-222.
13. Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA. 2001;286:208-216.
14. Sabar R, Kaye AD, Frost EA. Perioperative considerations for the patient on herbal medicines. Middle East J Anesthesiol. 2001;16:287-314.
15. Wolfman C, Viola H, Paladini A, Dajas F, Medina JH. Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from Passiflora coerulea. Pharmacol Biochem Behav. 1994;47:1-4.
16. Zanoli P, Avallone R, Baraldi M. Behavioral characterisation of the flavonoids apigenin and chrysin. Fitoterapia. 2000;71(suppl 1):S117-S123.
17. Akhondzadeh S, Naghavi HR, Vazirian M, Shayeganpour A, Rashidi H, Khani M. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther. 2001;26:363-367.
18. Dhawan K, Kumar S, Sharma A. Anti-anxiety studies on extracts of Passiflora incarnata Linneaus. J Ethnopharmacol. 2001;78):165-170.
19. Soulimani R, Younos C, Jarmouni S, Bousta D, Misslin R, Mortier F. Behavioural effects of Passiflora incarnata L. and its indole alkaloid and flavonoid derivatives and maltol in the mouse. J Ethnopharmacol. 1997;57:11-20.
20. Falter U, Gower AJ, Gobert J. Resistance of baseline activity in the elevated plus-maze to exogenous influences. Behav Pharmacol. 1992;3:123-128.
21. Lister RG. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl). 1987;92:180-185.
22. Rosa VP, Vandresen N, Calixto AV, Kovaleski DF, Faria MS. Temporal analysis of the rat's behavior in the plus-maze: effect of midazolam. Pharmacol Biochem Behav. 2000;67:177-182.
23. Shepherd JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT. Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety. Psychopharmacology (Berl). 1994;116:56-64.
24. Treit D, Menard J, Royan C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol Biochem Behav. 1993;44:463-469.
25. Pellow S, Chopin P, File SE, Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods. 1985;14:149-167.
26. Montgomery KC. The relation between fear induced by novel stimulation and exploratory behavior. J Comp Physiol Psychol. 1955;48:254-260.
27. Kulkarni SK, Reddy DS. Animal behavioral models for testing antianxiety agents. Methods Find Exp Clin Pharmacol. 1996;18:219-230.
28. Pellow S, File SE. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav. 1986;24:525-529.